UroGen Pharma Files 8-K on Financials
Ticker: URGN · Form: 8-K · Filed: 2024-11-06T00:00:00.000Z
Sentiment: neutral
Topics: financial-reporting, sec-filing
TL;DR
UroGen Pharma dropped an 8-K on Nov 6th detailing their financials. Check it out.
AI Summary
UroGen Pharma Ltd. filed an 8-K on November 6, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, providing an update on the company's financial status. The report is filed under the 1934 Act with the SEC.
Why It Matters
This filing provides investors with crucial, up-to-date financial information and operational results for UroGen Pharma Ltd., enabling informed investment decisions.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not indicate any immediate or significant risks.
Key Players & Entities
- UroGen Pharma Ltd. (company) — Registrant
- November 6, 2024 (date) — Date of earliest event reported
- 001-38079 (company) — SEC File Number
- 98-1460746 (company) — IRS Employer Identification No.
FAQ
What specific financial information is being reported in this 8-K?
This 8-K reports on UroGen Pharma Ltd.'s results of operations and financial condition, and includes financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on November 6, 2024.
What is the SEC file number for UroGen Pharma Ltd.?
The SEC file number for UroGen Pharma Ltd. is 001-38079.
Where are UroGen Pharma Ltd.'s principal executive offices located?
UroGen Pharma Ltd.'s principal executive offices are located at 400 Alexander Park Drive, 4th Floor, Princeton, New Jersey, 08540.
Under which section of the Securities Exchange Act is this report filed?
This Current Report is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 499 words · 2 min read · ~2 pages · Grade level 11.4 · Accepted 2024-11-06 08:01:53
Filing Documents
- d910412d8k.htm (8-K) — 24KB
- d910412dex991.htm (EX-99.1) — 74KB
- 0001193125-24-251712.txt ( ) — 233KB
- urgn-20241106.xsd (EX-101.SCH) — 3KB
- urgn-20241106_lab.xml (EX-101.LAB) — 18KB
- urgn-20241106_pre.xml (EX-101.PRE) — 11KB
- d910412d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibit Number Description 99.1 Press Release dated November 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 6, 2024 UROGEN PHARMA LTD. By: /s/ Chris Degnan Chris Degnan Chief Financial Officer